| Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug–Drug Interactions F Storelli, A Matthey, S Lenglet, A Thomas, J Desmeules, Y Daali Clinical Pharmacology & Therapeutics 104 (1), 148-157, 2018 | 60 | 2018 |
| Complex drug–drug–gene–disease interactions involving cytochromes P450: systematic review of published case reports and clinical perspectives F Storelli, C Samer, JL Reny, J Desmeules, Y Daali Clinical pharmacokinetics 57, 1267-1293, 2018 | 42 | 2018 |
| Abundance of P‐glycoprotein and other drug transporters at the human blood‐brain barrier in Alzheimer’s disease: A quantitative targeted proteomic study F Storelli, S Billington, AR Kumar, JD Unadkat Clinical Pharmacology & Therapeutics 109 (3), 667-675, 2021 | 40 | 2021 |
| Successful prediction of human fetal exposure to P-glycoprotein substrate drugs using the proteomics-informed relative expression factor approach and PBPK modeling and simulation O Anoshchenko, F Storelli, JD Unadkat Drug Metabolism and Disposition 49 (10), 919-928, 2021 | 27 | 2021 |
| The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans F Storelli, M Yin, AR Kumar, MK Ladumor, R Evers, PP Chothe, ... Pharmacology & Therapeutics 238, 108271, 2022 | 23 | 2022 |
| Physiologically‐based pharmacokinetic modeling for the prediction of CYP2D6‐mediated gene–drug–drug interactions F Storelli, J Desmeules, Y Daali CPT: pharmacometrics & systems pharmacology 8 (8), 567-576, 2019 | 20 | 2019 |
| Pharmacogenomics of oral antithrombotic drugs F Storelli, Y Daali, J Desmeules, JL Reny, P Fontana Current pharmaceutical design 22 (13), 1933-1949, 2016 | 16 | 2016 |
| Successful prediction of human steady‐state unbound brain‐to‐plasma concentration ratio of P‐gp substrates using the proteomics‐informed relative expression factor approach F Storelli, O Anoshchenko, JD Unadkat Clinical Pharmacology & Therapeutics 110 (2), 432-442, 2021 | 15 | 2021 |
| Is the protein-mediated uptake of drugs by organic anion transporting polypeptides a real phenomenon or an artifact? M Yin, F Storelli, JD Unadkat Drug Metabolism and Disposition 50 (9), 1132-1141, 2022 | 12 | 2022 |
| The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative … CRS Uppugunduri, F Storelli, V Mlakar, P Huezo-Diaz Curtis, A Rezgui, ... Frontiers in pharmacology 8, 451, 2017 | 11 | 2017 |
| Genotype‐sensitive reversible and time‐dependent CYP 2D6 inhibition in human liver microsomes F Storelli, J Desmeules, Y Daali Basic & clinical pharmacology & toxicology 124 (2), 170-180, 2019 | 10 | 2019 |
| Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes MK Ladumor, F Storelli, X Liang, Y Lai, OJ Enogieru, PP Chothe, R Evers, ... CPT: Pharmacometrics & Systems Pharmacology 12 (2), 261-273, 2023 | 5 | 2023 |
| Prediction of hepatobiliary clearances and hepatic concentrations of transported drugs in humans using rosuvastatin as a model drug F Storelli, CY Li, M Sachar, V Kumar, S Heyward, Z Sáfár, E Kis, ... Clinical Pharmacology & Therapeutics 112 (3), 593-604, 2022 | 4 | 2022 |
| Successful prediction of human brain Kp, uu of P-gp substrates using the proteomics-informed relative expression factor approach F Storelli, O Anoshchenko, JD Unadkat Clin Pharmacol Ther 10, 2021 | 2 | 2021 |
| Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model F Storelli, MK Ladumor, X Liang, Y Lai, PP Chothe, OJ Enogieru, R Evers, ... CPT: Pharmacometrics & Systems Pharmacology 13 (1), 118-131, 2024 | | 2024 |
| Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol F Rodieux, F Storelli, F Curtin, S Manzano, A Gervaix, KM Posfay-Barbe, ... Pharmaceuticals 16 (9), 1227, 2023 | | 2023 |
| Is Protein‐Mediated Uptake Of Drugs By OATPs, Via Protein‐Lipid Interaction, A Real Phenomenon Or An Artifact? M Yin, F Storelli, J Unadkat The FASEB Journal 36, 2022 | | 2022 |
| P22-Endobiotics for phenotyping of human cytochrome P450 enzymes: Use of metabolomics for the identification of new CYP2D6 endogenous biomarkers on healthy volunteers J Desmeules, G Magliocco, N Bararpour, F Storelli, Y Daali, A Thomas Drug Metabolism and Pharmacokinetics 35 (1), S28, 2020 | | 2020 |
| P83 CYP2D6 phenotyping in children treated with tramadol at the Emergency Department F Rodieux, F Storelli, S Manzano, A Gervaix, K Posfay-Barbe, C Samer, ... Archives of Disease in Childhood 104 (6), e51-e52, 2019 | | 2019 |
| Detection and Identification of Reactive Drug Metabolites Leading to Idiosyncratic Toxicity: Lapatinib as a Case Example. J Drug Metab Toxicol 9: 242. doi: 10.4172/2157-7609 … R Mohamed, F Storelli, J Sidibe, N Bararpour, J Desmeules vitro, 2018 | | 2018 |
